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Abstract
Introduction: HIV infection is a disease associated with chronic inflammation and immune activation. Antiretroviral therapy
reduces inflammation, but not to levels in comparable HIV-negative individuals. The HMG-coenzyme A reductase inhibitors
(statins) inhibit several pro-inflammatory processes and suppress immune activation, and are a logical therapy to assess for
a possible salutary effect on HIV disease progression and outcomes.
Methods: Eligible patients were patients enrolled in the Johns Hopkins HIV Clinical Cohort who achieved virologic
suppression within 180 days of starting a new highly active antiretroviral therapy (HAART) regimen after January 1, 1998.
Assessment was continued until death in patients who maintained a virologic suppression, with right-censoring of their
follow-up time if they had an HIV RNA . 500 copies/ml. Cox proportional hazards regression was used to assess statin use
as a time-varying covariate, as well as other demographic and clinical factors.
Results: A total of 1538 HIV-infected patients fulfilled eligibility criteria, of whom 238 (15.5%) received a statin while taking
HAART. There were 85 deaths (7 in statin users, 78 in non-users). By multivariate Cox regression, statin use was associated
with a relative hazard of 0.33 (95% CI: 0.14, 0.76; P=0.009) after adjusting for CD4, HIV-1 RNA, hemoglobin and cholesterol
levels at the start of HAART, age, race, HIV risk group, prior use of ART, year of HAART start, NNRTI vs. PI-based ART, prior
AIDS-defining illness, and viral hepatitis coinfection. Malignancy, non-AIDS-defining infection and liver failure were
particularly prominent causes of death.
Discussion: Statin use was associated with significantly lower hazard of dying in these HIV-infected patients who were
being effectively treated with HAART as determined by virologic suppression. Our results suggest the need for confirmation
in other observational cohorts, and if confirmed, the need for a clinical trial of statin use in HIV infection.
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Introduction
It is now well-recognized that HIV infection causes chronic
inflammation and immune activation. Untreated HIV infection
is associated with persistently high levels of pro-inflammatory
cytokines such as IL-1, IL-6, and TNF-alpha, coagulation
biomarkers and acute phase proteins such as fibrinogen, D-
dimer and high-sensitivity C-reactive protein [1,2]. These markers
of inflammation decline with the use of effective antiretroviral
therapy (ART), suggesting that active HIV replication is respon-
sible for this inflammatory response. However, many of these
inflammatory markers remain elevated despite suppression of HIV
replication with ART [3]. This may be due to low-level ongoing
HIV replication, other pathogens such as cytomegalovirus, and/or
translocation of gut-associated bacteria releasing lipopolysaccha-
ride (LPS) due to damage to gastrointestinal lymphoid tissue and
the intestinal lining [4,5]. Immune activation is also triggered
by pro-inflammatory cytokines, and their continuous activation,
together with thymic dysfunction and reduced T cell generative
potential, appears to accelerate the development of early immuno-
senescence [2,6,7]. Chronic inflammation and immune activation
accelerate organ damage to a variety of organ systems [8,9]. Car-
diovascular disease, malignancy, chronic kidney and liver disease
all appear to be occurring earlier and more frequently in HIV-
infected individuals, and have each been associated with this
process [10–13].
Given this scenario, it is possible that anti-inflammatory
treatments might improve HIV outcomes. ART is not sufficient,
and other measures that reduce inflammation might provide
additional benefit. The 3-hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitors (‘‘statins’’) are a class of drugs that have been
found to inhibit several pro-inflammatory processes independent
of their cholesterol-lowering effects. They decrease pro-inflamma-
tory cytokine levels and acute phase proteins, and also appear to
repress the activation of T lymphocytes [14–18]. In addition to
their beneficial effect on atherosclerosis, there is evidence that
statins may have other therapeutic benefits unrelated to anti-
inflammatory effects, such as a reduced risk of malignancy and
other non-cardiovascular disease complications including reduced
mortality from pneumonia, sepsis and influenza [19–27].
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individuals make them a logical drug class to examine in an
observational cohort of HIV-infected patients receiving ART.
Since ART is the cornerstone of HIV therapy, our analysis focused
on the association of statin use with clinical outcomes in patients
who maintained a full virologic suppression on ART.
Methods
This study was approved by the Johns Hopkins University
School of Medicine institutional review board. All subjects gave
written informed consent to have their clinical data collected
longitudinally for research purposes. The clinical investigation was
conducted according to the principles expressed in the Declaration
of Helsinki.
This analysis was conducted using data from patients in the
Johns Hopkins HIV Clinical Cohort. Briefly, this is a longitudinal
cohort study that enrolls patients who present for HIV care at the
Johns Hopkins HIV/AIDS Clinics. The refusal rate for partici-
pation is , 0.5%. Starting with their first clinic visit, demographic
data, all medication use, clinical diagnoses (HIV and non-HIV),
and comprehensive laboratory data are collected [28]).
This analysis examined survival after the initiation of a new
HAART regimen after cohort enrollment from January 1, 1998
through December 31, 2009. We further limited the analysis to
patients who achieved suppression of HIV-1 RNA level to
undetectable levels within 6 months of starting HAART (,=
400 copies/ml by first generation PCR assay or ,50 copies/ml by
ultrasensitive PCR assay). HAART was defined as use of a new
non-nucleoside reverse transcriptase inhibitor (NNRTI), protease
inhibitor (PI) or integrase strand transfer inhibitor (InSTI) with
two nucleoside analog reverse transcriptase inhibitors (NRTIs), or
use of an NNRTI plus PI and/or InSTI. The time origin was the
day of initiation of the new HAART regimen, and patients had to
have received at least 90 days of this regimen to qualify for
analysis. Statin use was coded as present if the statin was being
received by the patient at the time of, or after initiation of
HAART. A patient had to receive a statin for at least 30 days to be
considered as a statin user. Use of antiretroviral agents and statins
was determined based on prescribing, not filling of prescriptions,
so adherence was not directly assessed.
Mortality data, including date and cause of death, are obtained
by regular assessment of National Death Index and the National
Social Security Death Index. In addition, we routinely determine
deaths reported in the medical records from our institutions and
other facilities, by telephone or other communication from
relatives, friends, and other medical providers.
Cox proportional hazards regression was used to examine the
association of statin use with death. For this analysis, the initiation
of the HAART regimen was the time origin. The patient
contributed follow-up time only as long as s/he maintained a
suppressed viral load. Follow-up was right-censored if the patient
developed a viral load of greater than 500 copies/ml, or 90 days
after the last undetectable viral load measurement if no further
values were obtained. We examined statin use as a time-varying
variable, since patients who received statins were not always
receiving them at the time that the HAART regimen was started.
Analyzing statin use as time-varying minimizes immortal-time bias
(i.e., the patient must survive to receive the drug) that would occur
if statin use was analyzed simply as a fixed covariate. The risk sets
include whether a statin is being used or not at that particular time
after starting HAART, irrespective of whether the patient received
a statin at some other time during follow-up. Statin use was also
lagged by 90 days if it was discontinued so that a death would
attributed to a statin user if the statin had been used at least 90
days prior to the event.
Other variables that were examined included age, sex, race,
HIV transmission risk group, hemoglobin level at HAART
initiation, CD4+ cell count at HAART initiation, HIV-1 RNA
level at HAART initiation, specific HAART anchor drug
(NNRTI, PI, InSTI), calendar date of initiation of the HAART
regimen (, 2004 vs. $ 2004), prior ART use before starting
this HAART regimen prior AIDS-defining illness (ADI), and a
random total cholesterol level at HAART initiation. We compared
these patient characteristics of the sample by receipt of a statin
using the Wilcoxon rank-sum test for continuous variables or the
chi-squared test for categorical variables. Each of these variables
were also analyzed as covariates in a multivariate Cox regression.
Finally, we conducted a similar analysis to that described above
for the use of antihypertensive therapy. Since antihypertensive
therapy is often used in patients who are prescribed statins, we
wished to see if this therapy was associated with survival as a
method to assess for potential bias in the prescribing of these drugs
to individuals who were believed by their providers to be more
adherent or otherwise better candidates for cardiovascular risk
intervention.
Results
We analyzed the data from 1538 HIV-infected patients who
achieved virologic suppression within 6 months of starting
HAART and who subsequently maintained suppression until
death or until their data were censored. The median time to
censoring was 570 days (interquartile range: 268–1286 days), with
no significant difference in time to censoring between those
receiving and not receiving statins. The demographic and clinical
characteristics of the sample are shown in Table 1. The sample
characteristics reflected the demography of HIV-infection in
Maryland [29]. A total of 238 (15.5%) received a statin (69%
atorvastatin, 24% pravastatin, 7% rosuvastatin). Patients who
received statins were older and more likely to be white, and men
who have sex with men (MSM). They also had higher CD4+ cell
count and hemoglobin levels at baseline, and were more likely to
have previously received ART and to have had a prior ADI. Statin
users were more likely to have started HAART in the early part of
the decade than non-statin users. Statins were being used at the
time of HAART initiation in 122 (51.2%) of the patients who
received a statin. The median time on statin therapy was 745 days.
There were 85 deaths (7 on statins, 78 not on statins). By
multivariate Cox regression, statin use was associated with a
relative hazard (RH) of 0.33 (95% CI: 0.14, 0.76, p=0.009),
adjusting for CD4, HIV-1 RNA, hemoglobin and cholesterol
levels at the start of HAART, age, race, HIV risk group, prior use
of ART, year of HAART start, NNRTI vs. PI-based ART, prior
AIDS-defining illness, and viral hepatitis coinfection (Table 2). Of
these other characteristics, those that were also associated with an
increased risk of death in this multivariate analysis were a low
baseline hemoglobin level, older age, injection drug use (IDU), and
a prior ADI. Interactions between statin use and IDU,
heterosexual risk, sex, age . 50 years, race and prior ADI were
all tested, and none were significant, indicating that there is no
significant difference in the association between statin use and
survival by the individual categories of these variables. Statin use
was tested for and met the proportionality assumption for the Cox
proportional hazards model.
The causes of death are shown in Table 3. Malignancy, non-
AIDS-defining infection and liver failure were particularly
prominent. There was no proportional difference in death caused
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users, however the small number of deaths in statin users makes
meaningful statistical comparisons difficult. In addition, there were
15 deaths of unknown cause, some of which could have been due
to an unwitnessed cardiovascular event.
A total of 407 of the patients received antihypertensive therapy.
There was substantial overlap among users of statins and antihy-
pertensives, with 46% of those on statins also receiving
antihypertensive therapy. An analysis of antihypertensive therapy,
done similarly to the statin use analysis, showed no association
with survival (RH=1.11; 95% CI: 0.70, 1.78, p=0.64).
Discussion
We found that statin use was associated with a significantly
decreased hazard of dying. Statins have anti-inflammatory and
cellular immunological effects [14–18]. There is some evidence of
inhibition of HIV replication by statins in vitro [30,31], but this
effect was not seen clinically [15,32]. Atorvastatin was the most
commonly used statin, but we are unable to assess the association
between mortality and an individual type of statin due to the small
number of deaths in the statin using patients.
It is notable that a lower baseline hemoglobin was also strongly
associated with survival in these patients, as others have also found
[33–34]. ‘‘Anemia of chronic disease’’ is an anemia of chronic
inflammation, regulated by the peptide hormone hepcidin, whose
expression is increased during inflammation, infection, and iron
overload [35]. Arguably, anemia is a reasonable measure of chro-
nic inflammation when more specific inflammatory biomarkers
such are not routinely measured in clinical practice. Anemia has
been shown to be associated with survival in HIV-infected persons.
The strong association between anemia and survival in our
patients whose viral loads were suppressed suggests an indepen-
dent association between ongoing inflammation and mortality.
The small number of deaths among our patients who received
statins did not allow us to analyze whether there was a differential
association between statin use and death in those with low versus a
high hemoglobin levels, but there was not a significant interaction
between statin use and hemoglobin level and survival. Since other
inflammatory biomarkers or cellular markers of immune activation
were almost never measured in this cohort as part of clinical care,
we are unable to examine the association between these other
biomarkers, statin use and mortality. Other prognostic variables
included older age and non-MSM HIV transmission risk catego-
ries. Since both IDU and heterosexual contact were associated
with a higher risk of death than MSM, we assessed for interactions
between statin use and both IDU and heterosexual contact. These
interactions were not significant, indicating that the association
between statin use and death was similar in each HIV transmission
risk group. The baseline CD4+ cell count at the start of therapy
was not associated with mortality in the multivariate adjusted
analysis, suggesting that this may be a less important prognostic
variable among our patients who maintain virologic suppression
for causes of death that were not AIDS-defining illnesses.
No observational analysis can provide definitive evidence for the
efficacy of drug therapy, since selection bias can affect the
associations found. Since statins could have been selectively
prescribed to individuals thought to be more adherent or at lower
Table 1. Characteristics of the study population.
Total Statin Use No Statin Use
Category Subcategory N=1538 N=238 N=1300
Age (median years) 43 (36–49) 46 (40–53) 42 (36–47)**
Sex Male 1034 (67.2%) 172 (72.3%) 862 (66.3%)
Female 504 (32.7%) 66 (27.7%) 438 (33.7%)
Race Black 1112 (72.3%) 138 (58.0%) 974 (74.9%)**
White 292 (22.5%) 92 (38.7%) 292 (22.5%)**
Other 40 (2.7%) 8 (3.4%) 34 (2.6%)
HIV Risk Group
1 IDU 551 (34.3%) 48 (20.2%) 503 (38.7%)**
MSM 445 (28.9%) 91 (38.2%) 354(27.2%)**
Heterosexual
Contact
791 (51.7%) 106 (44.5%) 685 (52.7%)*
CD4 (median cells/mm
3) 225 (80–358) 270 (153–461) 200 (70–339)**
HIV-1 RNA (median copies/ml) 36,186 (1,633–145,950) 11,149 (88–126,816) 39,879 (3,252–
163,006)**
Hemoglobin (median g/dL) 12.7 (11.3–14.1) 13.2 (12.0–14.6) 12.7 (11.3–14.0)**
Total cholesterol (median mg/dL) 166 (141–194) 196 (168–238) 160 (134–188)**
Antihypertensive Use 407 (29.3%) 114 (46.3%) 293 (25.6%)**
Prior ART 933 (60.7%) 176 (73.9%) 757 (58.2%)**
Prior ADI 720 (46.8%) 132 (55.4%) 588 (45.2%)**
Viral hepatitis C co-infection 537 (34.9%) 61 (25.6%) 476 (36.6%)**
Year HAART started , 2004 875 (56.9%) 159 (66.8%) 716 (55.1%)**
$2004 663 (43.1%) 79 (33.2%) 584 (44.9%)
*0.01 , p-value , 0.5.
**p-value , 0.01.
1Categories are not mutually exclusive.
doi:10.1371/journal.pone.0021843.t001
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(variables associated with death) and several variables such as
MSM that were associated with use of statins. There were no
significant interactions between statin use and survival and HIV
risk group or several other variables. We also analyzed the
association of antihypertensive drugs, another class of therapy used
to manage cardiovascular disease risk, and that also tends to also
be used in patients who receive statins (60% overlap in our
population). There was no association between antihypertensive
therapy and survival. We were unable to assess other anti-
inflammatory and immunosuppressive drugs either because of
infrequent use (e.g., prednisone, cyclosporin), or over the counter
use that we did not capture (e.g. aspirin, NSAIDS). Since all of the
patients in this analysis maintained suppressed viral loads, we
believe that differential adherence to therapy was less likely to be a
significant issue. Nevertheless, it is certainly possible that statins
were used selectively in patients with a better survival prognosis
and that there are unmeasured confounders that would explain the
association we found. Even if statin use is clinically causing a
reduced mortality, it could be due to reasons other than an effect
on inflammation and immune activation.
In summary, we found that patients who maintained virologic
suppression on effective HAART appeared to derive additional
survival benefit from the use of a statin. If additional observational
data support this finding, a randomized clinical trial would be
warranted to confirm this association.
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